APEX-002

**APEX-002** (also designated APEX-52) is a low-dose, orally administered synthetic **psilocybin** formulation developed by **Apex Labs** for take-home use in treating mental health disorders. It acts primarily as a **serotonin 5-HT2A receptor agonist** and **ATP-binding cassette transporter modulator**, potentially offering therapeutic benefits for depression and anxiety with reduced psychoactive effects due to microdosing. Apex Labs has advanced multiple clinical studies, including IND submission to the FDA for pharmacokinetic and driving performance assessments, and Health Canada approvals for phase 2b trials evaluating efficacy in PTSD-associated depression.[1][3][5][9][11]

Brand names

APEX-52APEX52APEX 52

Other names

APEX-002-A01APEX002-A01APEX 002-A01APEX-002-A01-02APEX002-A01-02APEX 002-A01-02APEX-002-A01-03APEX002-A01-03APEX 002-A01-03APEX-002-A02APEX002-A02APEX 002-A02APEX-002-B01-02APEX002-B01-02APEX 002-B01-02